Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Gains from Investment Securities (2024 - 2025)

Prelude Therapeutics' Gains from Investment Securities history spans 2 years, with the latest figure at $2.3 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $2.3 million; the TTM value through Sep 2025 reached $2.3 million, changed N/A, while the annual FY2025 figure was $17000.0, 99.57% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was $2.3 million at Prelude Therapeutics, up from $3355.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.3 million in Q3 2025 and bottomed at -$458000.0 in Q1 2024.